Lifeboat Foundation

Circa 2018: In January 2017, while one of us was serving as a homeland security advisor to outgoing President Barack Obama, a deadly pandemic was among the scenarios that the outgoing and incoming U.S. Cabinet officials discussed in a daylong exercise that focused on honing interagency coordination and rapid federal response to potential crises. The exercise is an important element of the preparations during transitions between administrations, and it seemed things were off to a good start with a commitment to continuity and a focus on biodefense, preparedness, and the Global Health Security Agenda—an initiative begun by the Obama administration to help build health security capacity in the most critically at-risk countries around the world and to prevent the spread of infectious disease. But that commitment was short-lived.

Deadly diseases like Ebola and the avian flu are only one flight away. The U.S. government must start taking preparedness seriously.

Now, the descendant of that molecule — Gilead Sciences’ remdesivir — is being rushed to patients with infections from the novel coronavirus in hopes that it can reduce the intensity and duration of Covid-19 and ease the burden of the pandemic on health systems.

Remdesivir is now in the spotlight as scientists and governments scramble to hasten patients’ recovery and ease the pandemic’s burden on health systems.

Like other CoVs, it is sensitive to ultraviolet rays and heat. Furthermore, these viruses can be effectively inactivated by lipid solvents including ether (75%), ethanol, chlorine-containing disinfectant, peroxyacetic acid and chloroform except for chlorhexidine.

According to the World Health Organization (WHO), viral diseases continue to emerge and represent a serious issue to public health. In the last twenty years, several viral epidemics such as the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 to 2003, and H1N1 influenza in 2009, have been recorded. Most recently, the Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia in 2012.

In a timeline that reaches the present day, an epidemic of cases with unexplained low respiratory infections detected in Wuhan, the largest metropolitan area in China’s Hubei province, was first reported to the WHO Country Office in China, on December 31, 2019. Published literature can trace the beginning of symptomatic individuals back to the beginning of December 2019. As they were unable to identify the causative agent, these first cases were classified as “pneumonia of unknown etiology.” The Chinese Center for Disease Control and Prevention (CDC) and local CDCs organized an intensive outbreak investigation program. The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family.

Continue reading “Features, Evaluation and Treatment Coronavirus (COVID-19)” »

It is vital that would-be bombmakers be disabused of any notion that they could evade tough international sanctions. We need a country-neutral, reasonably predictable, more-or-less automatic sanction regime that puts all countries on notice, even friends of the powerful.

By Victor Gilinsky Henry Sokolski

Just as we’ve had to discard business-as-usual thinking to deal with the current worldwide health emergency; it’s time to get serious about the spread of nuclear weapons. It doesn’t have the immediacy of the coronavirus, but it will last a lot longer and is no less threatening. In particular, we need to fortify the Nuclear Nonproliferation Treaty (NPT), which is fifty years old this year and badly needs fixing. The April 2020 Review Conference will likely be postponed, which provides time to develop something more than the usual charade of incremental proposals that nibble at the problem.

Despite messages from some health officials to the contrary, it’s likely that a mask can help protect a healthy wearer from infection, says Benjamin Cowling, an epidemiologist at the University of Hong Kong. Both surgical masks and the more protective N95 respirators have been shown to prevent various respiratory infections in health care workers; there’s been some debate about which of the two is appropriate for different kinds of respiratory infection patient care. “It doesn’t make sense to imagine that … surgical masks are really important for health care workers but then not useful at all for the general public,” Cowling says.

Some argue that masking everyone would slow the spread of COVID-19—but the evidence is spotty.

Chronic lung diseases, including chronic obstructive pulmonary disease, asthma, lung cancer and pulmonary fibrosis, are the second leading cause of death in the world. Currently, only limited therapeutic options exist for chronic lung diseases; in particular, causative therapeutic approaches are missing. Lung transplantation remains the only available therapy for many patients with end-stage lung disease; however, the number of patients listed for lung transplantation by far surpasses the number of suitable donor organs.

Beyond lung transplantation, several approaches to repair and regenerate lung tissue, with the aim of restoring lung function, have made substantial progress in recent years and hold great promise for future therapies. Importantly, advancement in our understanding of the underlying pathogenesis of distinct chronic lung diseases will be crucial for the development of novel, targeted therapeutic approaches.

The mission of the European Respiratory Society (ERS) is to alleviate suffering from respiratory disease and promote lung health through research, knowledge sharing, and medical and public education. In support of this mission, the ERS hosts the annual Lung Science Conference (LSC) in Estoril, Portugal, which brings together leading experts (basic scientists, physician scientists and clinicians alike) on distinct topics of relevance to respiratory medicine. In addition, the ERS is strongly committed to encourage, nurture and mentor future generations of world class respiratory scientists and clinicians. The LSC represents one of the main platforms to encourage debate and interaction between young doctoral and postdoctoral scientists with established investigators. In particular, this is facilitated by special mentoring sessions and the Young Investigator Competition, which enables younger delegates to present themselves and their work to established investigators.

Working around the clock, scientists at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts can run about 2,000 COVID-19 tests per day. In places where testing is still scarce — which is to say much of the world — similar efforts can provide vital relief to public-health systems stretched to their limits. As they shutter their labs indefinitely, tens of thousands of scientists are volunteering to help the pandemic relief efforts in any way they can.

As labs shut down around the world, researchers are finding creative ways to donate their time, supplies and expertise.

Abbott Laboratories is unveiling a coronavirus test that can tell if someone is infected in as little as 5 minutes, and is so small and portable it can be used in almost any health-care setting.

The Army has a message for its retirees: Uncle Sam wants you to help fight the novel coronavirus.

A message sent by Defense Finance and Accounting Services, which processes and dispenses retiree pay, asked troops who had previously served in specific health care specialties to consider “re-joining the team” to address the current pandemic crisis. It’s signed by Lt. Gen. Thomas Seamands, deputy chief of staff for U.S. Army Personnel, G-1.

“We need to hear from you STAT!” reads the message, obtained by Military.com.